Research map: Beyond the Typical ICANS: Characterizing Non-ICANS Neurological Complications in CAR-T Therapy – A Retrospective Analysis

Back to the article

Papers in this map

  1. An anatomically comprehensive atlas of the adult human brain transcriptome · Michael Hawrylycz · 2012 · 3410 citations · Cited by this paper
  2. Cognitive dysfunction associated with cellular immunotherapy for cancer · 2026 · Related
  3. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma · Frederick Lundry Locke · 2021 · 1610 citations · Cited by this paper
  4. The molecular profile of gliomas in adolescents and young adults · 2026 · Related
  5. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial · Manali Kamdar · 2022 · 802 citations · Cited by this paper
  6. Immunogenomic Profiling Reveals Targets for Gene Therapy in Pediatric Brain Tumors · 2026 · Related
  7. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline · Bianca D. Santomasso · 2021 · 420 citations · Cited by this paper
  8. Emotional distress impairs immune checkpoint blockade efficacy in recurrent high-grade glioma: Insights from tumor in situ fluid analysis · 2026 · Related
  9. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells · Philipp Karschnia · 2019 · 359 citations · Cited by this paper
  10. Mutational signature stratification of recurrent gliomas reveals distinct patterns of genomic traits · 2026 · Related
  11. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy · Oliver Van Oekelen · 2021 · 279 citations · Cited by this paper
  12. Emerging blood-based biomarkers for the detection of parenchymal brain metastasis: Current progress and future perspectives · 2026 · Related
  13. Rapidly changing myeloma epidemiology in the general population: Increased incidence, older patients, and longer survival · Ingemar Turesson · 2018 · 181 citations · Cited by this paper
  14. ASL-based Exchange Time Mapping for Differentiation of High-Grade Glioma and Brain Metastases · 2026 · Related
  15. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review · Shakira Jeanene Grant · 2022 · 147 citations · Cited by this paper
  16. Disturbance of functional connectivity in patients with low grade glioma is associated with worse progression–free survival · 2026 · Related
  17. In the Eye of the Storm: Immune‐mediated Toxicities Associated With CAR‐T Cell Therapy · Jorge Garcia Borrega · 2019 · 134 citations · Cited by this paper
  18. The Cell Surface Proteome of Malignant Peripheral Nerve Sheath Tumors Reveals Therapeutic Targets · 2026 · Related
  19. Chemotherapy-induced reversal of ciltacabtagene autoleucel–associated movement and neurocognitive toxicity · Charlotte Graham · 2023 · 70 citations · Cited by this paper
  20. Phase I Trial and Pharmacokinetic Study of Berubicin (RTA 744) in Patients with Recurrent or Refractory High-Grade Gliomas · 2026 · Related
  21. Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee · Charlotte Graham · 2025 · 66 citations · Cited by this paper
  22. Trends Analysis of Non-Hodgkin Lymphoma at the National, Regional, and Global Level, 1990–2019: Results From the Global Burden of Disease Study 2019 · Wenwen Cai · 2021 · 65 citations · Cited by this paper
  23. Neurotoxicity and Rare Adverse Events in BCMA-Directed CAR T Cell Therapy: A Comprehensive Analysis of Real-World FAERS Data · Moataz Ellithi · 2024 · 38 citations · Cited by this paper
  24. BCMA-CAR T-cell treatment–associated parkinsonism · Juliane Gust · 2023 · 37 citations · Cited by this paper
  25. Chimeric antigen receptor T‐cell therapy toxicities · Uri Greenbaum · 2020 · 32 citations · Cited by this paper
  26. Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome · Shakthi Bhaskar · 2022 · 22 citations · Cited by this paper
  27. Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy · Leon D. Kaulen · 2025 · 18 citations · Cited by this paper
  28. Comparison between MRI-negative and positive results and the predictors for a poor prognosis in patients with idiopathic acute transverse myelitis · Yu Zhou · 2024 · 9 citations · Cited by this paper
  29. Retrospective Comparison of the Roles of Tocilizumab and Siltuximab in the Management of Toxicity in CAR-T Cell Therapy for Relapsed/Refractory B-NHL · Rui Liu · 2024 · 2 citations · Cited by this paper

Source: OpenAlex (CC0)